Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy

Condition(s) studied

Investigational drug(s) / intervention(s)

molecular analysis: molecular analysis on histological blocks

Study summary

After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.

The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature.

The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.

Eligibility

Primary outcome measure(s)

• Molecular anomalies retained after biological interpretation and allowing the differentiation of refractory patients from long-term responder patients. — Through study completion, an average of 1 year
  Refractory patients are defined as any patient progressing through the first therapeutic line of platinum-based chemotherapy. Long responders are defined as any patient who has not progressed within 5 years of the end of platinum salt treatment.

Trial sites (1)

More Centre Jean Perrin trials in France

Other trials for the same condition